Lataa...
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first‐in‐human trial in healthy postmenopausal women
AIMS: Preterm birth remains a significant risk for later disability. The selective inhibition of the prostaglandin F(2α) receptor has significant advantages for a tocolytic. The prodrug OBE022 and its metabolite OBE002 are novel prostaglandin F(2α) receptor antagonists under development for treating...
Tallennettuna:
| Julkaisussa: | Br J Clin Pharmacol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6046484/ https://ncbi.nlm.nih.gov/pubmed/29708281 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13622 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|